GlassScriptPhysician profile
Francisca Paz
NPI 1992325682
$10,562.38
in general payments reported to CMS, 2019-2025
34 companies · $2,638 in 2025
The $2,638 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,654 · 2022: $1,595 · 2023: $1,299 · 2024: $3,377 · 2025: $2,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,271 · Travel and Lodging: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,271.22 |
| Travel and Lodging | $2,042.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,439.33 | 2024-2025 | Symplicity G3, Corevalve Evolut R, Affera Mapping System |
| Astrazeneca Pharmaceuticals LP | $1,081.96 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Merck Sharp & Dohme LLC | $761.05 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $752.61 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $702.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.00 | 2021-2024 | Jardiance |
| Amgen INC. | $416.22 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $384.76 | 2021-2024 | Nexletol |
| Pfizer INC. | $382.53 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $369.99 | 2021-2024 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $320.38 | 2021-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $259.26 | 2022-2024 | Xarelto |
| Abiomed | $179.98 | 2023-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $151.62 | 2025 | |
| Biocomposites INC | $151.18 | 2024-2025 | Stimulan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $122.87 | 2022 | |
| Janssen Scientific Affairs, LLC | $108.70 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $71.32 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $65.35 | 2021 | |
| Azurity Pharmaceuticals, INC. | $50.61 | 2023-2025 | Edarbi, Edarbi |
| Actelion Pharmaceuticals US, INC. | $50.42 | 2024-2025 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $38.24 | 2022-2023 | |
| Stryker Corporation | $36.00 | 2025 | Flowtriever |
| Boston Scientific Corporation | $30.51 | 2023 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $28.87 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $27.52 | 2021 | |
| Cvrx, INC. | $27.05 | 2023 | Barostim Neo System |
| Atricure, INC. | $21.27 | 2022 | |
| Scpharmaceuticals INC. | $20.28 | 2025 | |
| Cleerly, INC. | $19.68 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Novo Nordisk INC | $19.38 | 2025 | Wegovy |
| Itamar Medical INC | $17.06 | 2022 | |
| Lundbeck LLC | $17.02 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francisca Paz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.